Skip to main content

Table 1 Clinical characteristics in T1G3 patients treated with BCG

From: Expression level of dihydropyrimidine dehydrogenase is associated with clinical outcome in patients with T1G3 bladder cancer treated with Bacillus Calmette-Guerin

 

Overall

Age, mean ± SE

66.9 ± 2.3

Gender, men/women

23 (82.1%)/5 (17.9%)

Concomitant CIS

7 (25.0%)

Multiple disease

19 (67.9%)

LVI positive

18 (64.3%)

Recurrence

13 (46.4%)

Progression

5 (17.9%)

Death

1 (2.2%)

Disease specific death

0 (0.0%)

  1. SE: standard error; CIS: carcinoma in situ; LVI: lymphovascular invasion.
Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us